Howard J. A. Carp1, 2 , David Soriano2, 3 and Matityahu Zolti4
(1)
Department of Obstetrics & Gynecology, Sheba Medical Center, Tel Hashomer, 52621, Israel
(2)
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
(3)
Endometriosis center, Sheba Medical Center, Tel Hashomer, Israel
(4)
Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel
Howard J. A. Carp
Email: carp@netvision.net.il
1 Introduction
Endometriosis is a chronic and recurrent condition in which endometrial-like tissue is found outside the uterus. Endometriotic lesions may be superficial, deeply infiltrating or ovarian. Superficial lesions appear as black, dark brown or bluish coloured lesions, or as small cysts, covering old hemorrhages, surrounded by various degrees of fibrosis. Lesions are mostly located in the peritoneum, pouch of Douglas, ovaries or sacroiliac ligaments. Endometriosis is defined as deeply infiltrating if penetrating more than 5 mm under the peritoneum [1]. Infiltrating lesions may invade adjacent organs (bladder, bowel or rectum) leading to a wide range of symptoms. Endometriotic lesions may be found in organs as distant as liver, lung or brain. In the ovaries, endometriosis may form endometriomas, with smooth walled cysts filled with a “chocolate” like material. Some women with endometriosis experience extreme pain and/or infertility, while others have less or minor symptoms, or the symptoms appear late in the course of the disease. Endometriotic lesions are surrounded by an inflammatory reaction which may lead to adhesions ranging from filmy synechia to dense adhesions which obliterate all planes of separation between the various organs involved.
The exact prevalence is unknown but estimates range from 5 to 10 % of women of reproductive age, to 50 % of infertile women [2, 3]. The combination of laparoscopy and histological confirmation is the gold standard for diagnosis of the disease. However, the condition may be suspected by the symptoms, signs, gynecological examination, and imaging techniques. Invasive surgical techniques are not always essential for managing the disease. However, in cases of severe symptoms and findings it can offer a relief for long time. Diagnosis, although less accurate, can be obtained by non-invasive methods such as transvaginal sonography which consider today as the first method for evaluation or magnetic resonance imaging. Ovarian endomeriomas may be diagnosed by either imaging technique, Adhesions can be diagnosed by transvaginal ultrasound, with the sliding sign technique. This technique assesses whether the uterus and ovaries move freely over the adjacent organs and tissues. Magnetic resonance imaging can be useful in diagnosing all locations of endometriosis. A detailed non-invasive diagnosis of extension within the pelvis can facilitate the choice of a safe and adequate surgical or medical approach. Treatment is dependent on the patient's age and needs. Treatment may be required to reduce pain, enhance fertility, or both or to prevent recurrence. However, except in cases of a solitary nodule which is completely resected or focal lesions such as endometriosis, in scar, complete resolution is not possible as yet. Presently all treatment modalities provide temporary relief. This chapter describes the features of endometriosis which are relevant to progestogen treatment. It is not intended to be a full treatise on endometriosis.
2 Inflammatory Reaction Around Endometriotic Deposits
As long ago as 1922, it was recognized that neoangiogenesis, fibrosis and hemosiderin accumulation were intrinsic microscopic characteristics of the endometriotic lesion. In endometriosis, peritoneal macrophages are activated, and increased cytokine production is found. However, the macrophages cannot carry out phagocytosis of the ectopic endometrium [4]. The ectopic endomerium has been reported to contain a protein (Endo 1) [5] which binds to peritoneal macrophages, increasing their production of interleukin 6, and reducing their phagocytic ability [6]. Hence, there is compromised immune surveillance in endometriosis. There is also evidence of compromised innate immunity and natural killer cell activity in the peritoneal fluid in endometriosis [7]. In endometriosis, the peritoneal fluid has high concentrations of cytokines, growth factors, and angiogenic factors, derived from the lesions themselves, the secretory products of macrophages and other immune cells. Once endometriotic lesions are formed, they secrete several proinflammatory cytokines which recruit macrophages and T lymphocytes in to the peritoneum such as IL-1, IL-8, TNF-α, IFN-γ. Several angiogenic factors are also expressed by endometriotic lesions such as IL-1, IL-6, IL-8, EGF, Fibroblast growth factor, insulin-like growth factor, vascular endothelial growth factor (VEGF), and Endo I. thus explaining the angiogenesis in the peritoneal cavity [8]. Figure 9.1 shows the intense inflammatory reaction with ikntense angiogenesis around the lesion. Immune cells such as NK cells mediate the inflammatory reaction associated with endometriosis. It has been even been suggested that the peritoneal fluid may be an active promoter of growth of endometrial deposits by lipid peroxidation [9, 10]. These oxidants may stimulate endometrial-cell growth.
Fig. 9.1
Inflammatory reaction and neoangiogenesis around endometriotic lesion. U Uterus, US uteroscacral ligaments. These can be seen to be edematous and inflamed. E endometriotic lesion, BV dilated blood vessels
Endometriosis has many features of an autoimmune disease as there is increased polyclonal B-cell activity, high B-cell and T-cell counts, but with abnormal function [11, 12], and reduced natural-killer-cell activity [7, 12] High serum concentrations of IgG, IgA, and IgM autoantibodies [12, 13] and anti-endometrial antibodies have been reported [14]. Additionally, there is a high concordance of other autoimmune diseases or phenomena in women with endometriosis such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, autoimmune thyroid disease, allergies, asthma and eczema [15]. Several studies have reported an association between autoimmune thyroid disease and endometriosis associated infertility, as shown by a high prevalence of positive anti-TPO antibodies [16].
Rather than being autoimmune in origin, the inflammatory reaction may be a response to the invasive properties of ectopic endomerium. Ectopic endometrial tissue fragments can attach to and invade the peritoneal surface. Matrix metalloproteinases (MMP) degrade extracellular matrix. MMP 7 and MMP 11 are normally expressed in the endometrium during menstrual breakdown and subsequent oestrogen-mediated endometrial proliferation. MMP 7 and MMP 11 are normally suppressed by progesterone during the secretory phase [17]. However, the ectopic endometrium is resistant to the effects of progesterone action due to non expression of the enzyme 17β hydroxysteroid dehydrogenase in women with endometriosis. Persistent expression of MMP might enable endometrial tissue to invade the peritoneal surface.
Survival of ectopic endometrial tissue in the peritoneal cavity is crucial for the establishment of viable implants. Downregulation of proapoptotic genes and upregulation of antiapoptotic genes of the BCL2 and BAX families, have been reported endometriotic lesions [18]. Hence, there may be an intrinsic abnormality in endometriosis that permits ectopic endometrium to attach, survive, invade, and establish a blood supply.
Nuclear factor kappa B (NF-kB) may be crucial for mediating several biochemical processes associated with endometriosis [19]. NF-kB is activated by proinflammatory cytokines and oxidative stress and is increased in endometriotic lesions. NF-kB activation leads to the expression of a number of genes involved in inflammation, such as IL-1, IL-6, IL-8, and cyclooxygenase-2 [20]. Endometriotic tissue has been shown to activate NF-kB [21]. By activating proinflammatory genes, NF-kB perpetuates inflammation and macrophage recruitment. In addition to the inflammatory cascade, NF-kB regulates genes involved in antiapoptosis, tissue invasion, cell proliferation, and angiogenesis. In healthy women, NF-kB-DNA binding is decreased in the secretory phase relative to the proliferative phase, which may be due to the anti-inflammatory action of progesterone [21] . However, in women with endometriosis, NF-kB-DNA binding remains elevated during the secretory phase [22].
2.1 Effect of Sex Hormones on Inflammatory Reaction
Hormonal alterations may influence the ability of endometriotic cells to proliferate, attach to the mesothelium and evade immune mediated clearance [23]. Figure 9.2 shows the effect of various hormones and medications on the development of endometriosis. Endometriotic implants have increased expression of aromatase. and decreased expression of 17β-hydroxysteroid dehydrogenase [24] The consequence is a marked increase in the locally bioavailable estradiol concentration. Estradiol stimulates the production of prostaglandin E2 which further stimulates aromatase activity [25]. In addition to estrogen dependence and biosynthesis, there is progesterone resistance in the pathophysiology of endometriosis [26]. Endometriotic lesions have reduced progesterone receptor expression when compared to eutopic endometrium, and an absence of progesterone receptor-B [27]. It has been reported that Akt (protein kinase) may be overactive, thus promoting progestogen resistance, and promotes the survival and proliferation of the diseased cells [28]. Increased Akt may be sufficient to downregulate progesterone receptor protein expression.
Fig. 9.2
Medications acting on endometriosis. Red arrows = stimulate endometriosis. Blue arrows indicate agents inhibiting endometriosis. SERM’s = selective estrogen receptor modulators, SPRMS = selective progesterone receptor modulators
HOX genes, are dynamically expressed in the endometrium, where they are necessary for endometrial growth, differentiation, and implantation. In the human endometrium, the expression of HOXA10 and HOXA11 has peak expression at implantation in response to rising progesterone levels. However, maximal HOXA10 and HOXA11 expression does not occur in endometriosis, due to altered progesterone receptor expression or a dysregulated progesterone response. Consequently, other mediators of endometrial receptivity that are regulated by HOX genes, such as pinopodes, αvβ3 integrin, and IGFBP-1, are downregulated in endometriosis. HOXA10 hypermethylation may silence HOXA10 gene expression and account for decreased HOXA10 in the endometrium of women with endometriosis. Silencing of progesterone target genes by methylation is an epigenetic mechanism that mediates progesterone resistance. The relatively permanent nature of methylation may explain the widespread failure of treatments for endometriosis-related infertility [29].
Normal apoptosis mechanisms are suppressed in endometrial cells from women with endometriosis and within endometriotic lesions. Increased estrogen availability due to local estradiol synthesis and increased estrogen sensitivity lead to exaggerated protein kinase (Akt) activation and apoptosis inhibition [30].
2.2 Innervation of Endometriosis
In endometriosis there appears to be neoneurogenesis. The functional layer of eutopic endometrium (functionalis and basalis) is highly innervated in endometriosis [31] as are the ectopic lesions [32]. Small nerve fiber density assessed in endometrial biopsies from women with early stage endometriosis was 14 times higher than in biopsies from healthy controls [33]. Pain severity scores correlated with the presence of nerve fibers in both peritoneal and rectovaginal endometriotic lesions [34]. Persistent stimulation of nascent nociceptors in endometriotic lesions by inflammatory mediators may lead to central sensitization and neuropathic pain [35].
3 Evasion of Immune Clearance
Normally, endometrial cells which have been shed into the peritoneum are cleared by the immune system. Failure of the clearance mechanism may predispose to the implantation and growth of endometriosis. Endometrial cells have been found to be resistant to lysis by natural killer (NK) cells when compared to the endometrium from women without disease [7]. Shedding of intercellular adhesion molecule-1 (ICAM-1) by endometrial stromal cells from women with endometriosis may be one mechanism whereby these cells escape NK mediated clearance [36]. Impaired NK cell function (by downregulation of the NK1receptor and compromised macrophage function in endometriosis may further contribute to decreased clearance of lesions.
4 Treatment
No treatment of endomeriosis is curative, but based on tiding the patient over with pain relief, or optimising the possibility of fertility. The principles of treatment are summarised in Table 9.1 and include:- 1. Debulking and restoration of anatomy, by surgery. 2. Reduction of the estrogen required to maintain endometriosis. This can be achieved with GnRH analogs or Danazol 3. Reduction of the inflammatory response. This approach uses progestogens or anti-inflammatory agents. The object of medical management is to control pain and prevent recurrence of endometriosis. Medical treatment can be used on its own or as an adjunct to surgery.
Table 9.1
Management of endometriosis: therapeutic intervention
|
Debulking |
Surgery |
|
Estrogen reduction |
1. Danazol 2. GnRH analogues 3. GnRH antagonists |
|
Reducing inflammatory response |
1. Progestogens 2. Oral contraceptive pills 3. Anti-inflammatory agents |
|
Endometrial atrophy |
1. LNG-IUS 2. Gestrinone |
4.1 Surgical Treatment
Surgical excision or ablation and adhesiolysis is an effective initial approach to treatment, whether for pain relief, or to enhance fertility [37]. There is widespread consensus that lesions should be excised where possible, especially deep endometriotic lesions [38]. Moreover, the surgery may be complex, particularly if other organs are involved such as bowel bladder or ureter. Moreover, even after excision which seems to be complete, there is often recurrence. Recurrence has been reported to vary from 10 to 55 % within 12 months [39], with recurrence affecting approximately 10 % of the remaining women each additional year [40]. The necessity for repeat surgery is higher in women younger than 30 years at the time of surgery [41]. Initial surgery produces better results than subsequent surgical procedures [42].
When there is deep infiltrating endometriosis, there is a dilemma. Incomplete resection may reduce symptomatic outcomes [43], but very extensive surgery increases the risk of ureteric and rectal injuries etc. [44]. Hence, it is clear is that surgical experience and expertise are required for endometriosis surgery, and that surgery should preferably be undertaken in centers of expertise.
Observational studies have suggested improved pain outcomes for women who undergo hysterectomy for Stage IV endometriosis [45]. However, hysterectomy is obviously reserved for women who do not require fertility. 96.9 % of women become asymptomatic after menopause [46]. It should also be borne in mind that as long as the patient has endogenous estrogen production, surgery is not curative, and in most cases only cytoreductive.
4.2 Progestogens
4.2.1 Mode of Action
Progestogens have been used to control the pain of endometriosis for many years. Progestogens are effective at a number of different levels. Some progestogens have anti-gonadotropic actions effect which inhibits ovarian function to create a hypoestrogenic environment. It was assumed that by directly acting on endometrial progesterone receptors progestogens may induce decidualization and atrophy of endometriosis. Progestogens can also reduce the inflammatory response. Hence, progestogens are frequently used as first-line therapy for the treatment of endometriosis. Progestogens do not reduce estradiol levels as much as GnRH agonists. Progestogens are advantageous over GnRH analogs as progestogens do not induce a medical menopause and are not associated with hot flushes and other hypo-estrogenic side effects such as decreased bone mineral density.
The concept of progestogens acting on progesterone receptors and inducing decidualization as in normal endometrium does not seem to be valid. Endometriotic foci contain very few progesterone receptors [47]. The enzyme 17β hydroxysteroid dehydrogenase is absent in endometriotic tissue [48] and cannot be activated by progestogens. Progestogens also reduce the synthesis of their own receptors, which down regulates the sensitivity of the implants during long-term treatment.
Progestogens most probably acts by reducing the inflammatory response. TNF-α and estradiol induce the proliferation of endometriotic stroma cells via NF-kB, whereas progestogens reduce TNF-α induced NF-kB activation [49]. Progesterone itself is associated with decreased IFN-γ & increased IL-10 in endocervical fluid [50], upregulation of LIF mRNA expression in vitro. [51], and inhibits NK cell activity. The synthetic progestogen dydrogesterone has also been shown to modulate immune responses via suppression of IL-8 production in lymphocytes, inhibition of IFN-γ and increasing levels of IL-4 [52]. The increase in nitric oxide production seen with dydrogesterone may also play an important anti-inflammatory role [53].
4.2.2 Different Progestogens
Many progestogens have been have been used for the treatment of endometriosis. These include medroxyprogesterone acetate (administered by intramuscular injection), desogestrel, dienogest, cyproterone acetate, dydrogesterone etc. administered orally, either alone, or in combination with oestrogens in the combined oral contraceptive pill or levonorgestrel absorbed from an intrauterine contraceptive device. Progestogens have many beneficial effects. However, the results do not differ very much from the use of the combined estrogen progestin oral contraceptive pill. Some specific progestogens are described below.
Dydrogesterone
Dydrogesterone is a stereoisomer of progesterone manufactured by treating progesterone with ultraviolet light. Dydrogesterone stimulates the progesterone receptor directly without affecting progesterone levels. Dydrogesterone also binds the receptor 50 % more than progesterone itself [54]. Dydrogesterone does not stimulate the androgen, glucocorticoid or estrogen receptor.
There are numerous small comparative studies and case reports of dydrogesterone in endometriosis since the 1960s. Schweppe [55] summarized seven control studies of dydrogesterone. Doses between 10 and 60 mg/day, were used for various numbers of days per cycle, and over periods of 3–9 months. The majority of women became symptom-free or experienced a significant reduction in the number/severity of symptoms. These findings have been supported by laparoscopic examination in several of the studies. There was an overall success rate of approximately 70–90 %. Laparoscopic examination in several of the studies supported these findings. However, a Cochrane review published in 2012 [56] which included 13 randomised controlled trials evaluating the use of progestogens, included found only one RCT for dydrogesterone [57]. Sixty-two women were randomized to dydrogesterone or placebo. Only 39 women completed the study and underwent a second look laparoscopy. There was no significant improvement in objective efficacy at 6 months compared to placebo (OR 0.53, 95 % CI 0.14–1.94) Nor were there any differences observed in the change in pain score at 12 months of follow up (OR 0.80, 95 % CI 0.27–2.37; NS). However, the wide confidence intervals and small number of patients indicates that Schweppe’s [55] figures are probably more relevant.
Cyclic application of dydrogesterone has also been shown to induce regular menstruation with reduced blood loss and fewer days of bleeding, combined with excellent symptomatic relief, in women suffering from dysmenorrhea. Dydrogesterone is especially useful in patients desiring pregnancy Because dydrogesterone does not inhibit ovulation it can be used for symptomatic treatment of pain, reduction of bleeding problems and cycle control.
Dienogest
Dienogest is a synthetic orally active progestogen. As dydrogesterone, dienogest is highly selective for the progesterone receptor and exerts a strong progestational effect. However, dienogest differs from dydrogesterone in that it has a moderate antagonist action on the androgen receptor, and has a moderate antigonadotropic effect [58]. However, there is no androgenic, glucocorticoid, mineralocorticoid activity or estrogenic activity. The therapeutic dose (2 mg) inhibits ovulation in healthy women with normal menstrual cycles [59]. However, dienogest only moderately reduces oestrogen levels, hence, dienogest does affect bone mineral density [60]. Dienogest does not reduce sex hormone-binding globulin, is bound unspecifically to albumin and does not accumulate using oral doses of 2 mg/day [61].
Two prospective placebo controlled randomized studies assessed dienogest 2 mg daily against placebo [58] or versus leuprorelin depot [60]. Both trials showed a significant improvement in endometriosis-related symptoms, and a similar effectiveness to GnRH agonist therapy. However, the bleeding pattern differed substantially between the two groups. In the leuprolide group most women had infrequent bleeding in the first 90 days and amenorrhea after prolonged treatment. In the dienogest group prolonged and irregular bleeding were frequent in the first 90 days of treatment. Bleeding problems occurred in up to 80 % of patients within the first 3 months of treatment.
In a single-arm extension study of treatment for 15 months and follow-up 6 months after discontinuation of treatment, dienogest was shown to reduce pain symptoms with normalisation and long term relief of symptoms even after treatment discontinuation.
Dienogest has a good safety and efficacy profile, with good tolerability, antiandrogenic action and weak antigonadotropic activity, combined with typical characteristics of 19-norprogestins: strong suppressive action on the endometrium in low doses, a short half-life and high bioavailability [62]. However, there are no trials comparing the efficacy and tolerability of dienogest to OCPs or other progestogens.
Medroxy Progesterone Acetate (MPA)
MPA can be administered orally in a dose of 15–50 mg orally or injected as a depot form (DMPA). Bergqvist et al. [63] compared MPA to placebo. There was a greater quality of life after MPA and pain relief. Telimaa et al. [64] reported the results of a prospective, randomized trial comparing MPA to Danazol. A 50 % regression rate of ectopic implants and 13 % partial regression with scar formation was reported in the treatment group compared to 12 and 6 %, respectively, in the placebo group, and a net reduction in pain symptoms after treatment compared to placebo. (OR = 0.70, CI −8.61 to −5.39; P < 0.00001). When Danazol and MPA were compared, both alleviated endometriosis-associated pelvic pain, lower back pain and defecation pain, but they did not differ from each other in these actions. The authors concluded that because of good efficacy and tolerance, high-dose MPA is a useful alternative in the hormonal treatment of endometriosis. However, MPA has glucocorticoid and androgenic effects. Brown et al. [56], have reported significantly more cases of acne (six versus one) and oedema (11 versus one) in the medroxyprogesterone acetate group compared with placebo. The dose is 20 mg to 100 mg daily. Harrison and Barry-Kinsella [65] published the results of a placebo controlled trial. Initial and second-look laparoscopy were performed to grade the lesions according to the revised American Fertility Society stages. Surprisingly, both MPA and placebo therapy achieved similar statistically significant reductions in stages and scores at second-look laparoscopy. However, MPA was more effective in improving overall well-being. The authors concluded, that as both MPA and placebo were equally effective in treating endometriosis over a 3-month period, and questioned the role of using MPA altogether.
MPA can also be administered intramuscularly in a depot form (DPMA). DPMA is long acting, and a 150 mg. dose may only need to be repeated after 3 months. Vercellini [66] compared 150 mg of depot medroxyprogesterone (DMPA) every 3 months with a 20 μg oral contraceptive pill (OCP) with 50 mg danazol. Both the pill and danazol were taken for 3 weeks out of 4. The primary endpoint was the degree of satisfaction at the end of therapy. Pain reduction with MPA was as effective as danazol. DPMA has also been compared to leuprolide [67]. Symptoms of dysmenorrhoea were significantly reduced in the DMPA group at 6 months compared with leuprolide (OR 0.19, 95 % CI 0.05–0.69; P = 0.01) but this effect was short lived, and not present at the 12 months follow-up (OR 0.63, 95 % CI 0.37–1.08). There were no differences between groups at 12 months follow up, regarding dyspareunia after 6 months. At 12 months fewer women in the leuprolide group reported dyspareunia (OR 4.83, 95 % CI 2.14–10.93).
Side effects include breakthrough bleeding in approximately 40 % of patients, nausea, breast tenderness, fluid retention and depression.
Cyproterone Acetate
Vercellini [68] compared 12.5 mg cytoproterone acetate daily to a continuous monophasic OCP once daily (0.02 μg ethinyl estradiol and 0.15 mg desogestrel). The primary endpoint, as in their previous study, was the degree of satisfaction at the end of therapy. A change in severity of symptoms was also measured by a 100 mm visual analogue score and a 0–3 point verbal rating scale. Cyproterone however, has significant anti-androgenic effects.
Levonorgestrel Intrauterine System (LNG-IUS)
The LNG-IUS is a contraceptive intrauterine device (IUD). As it releases norgesterel in a constant fashion, it lessens the excess bleeding associated with other IUD’s, and may even lead to amenorrhea. The LNG-IUS is therefore indicated for women with menorrhagia and dysfunctional bleeding. The constant release of levonorgestrel leads to mean plasma concentrations between 100 and 200 pg/ml [69]. Endometrial exposure to LNG induces endometrial atrophy. Hence the LNG-IUS can only be used for endometriosis in women who do not desire fertility, and who are prepared to accept amenorrhea.
Several small RCTs have compared the use of LNG-IUS in endometriosis to GnRH agonists and Depot medroxyprogesterone acetate [70]. The mechanism by which the LNG-IUS decreases endometriosis related symptoms is unclear, as the LNG-IUS does not inhibit ovulation nor does it induce a hypoestrogenic state. It has been suggested that the LNG-IUS acts by decreasing the expression of glandular and stromal estrogen and progesterone receptors in the ectopic endometrium [71]. With the LNG-IUS a reduction of the severity of endometriosis has been seen at laparoscopy [72, 73]. The echographic size of recto-vaginal lesions under has also been seen on ultrasound under LNG-IUS treatment [74]. The LNG-IUS has been shown to reduce pain [75]. Tanmahasamut [76] compared treatment with the LNS-IUS after laparoscopic conservative surgery to expectant management. There was a significant reduction in dysmenorrhoea [5.0 cm vs 8.1 cm on the visual analogue scale (VAS)] and non-cyclic pelvic pain (VAS 2.2 cm vs 4.8 cm) but no effect on dyspareunia. The LNG-IUS is as effective as DMPA with no impact on bone mineral density [77]. Bayoglu et al. [78] compared the efficacy of the LNG-IUS with the GnRH analogue gosareline on endometriosis related chronic pelvic pain in patients with severe endometriosis during 12 months. Both treatment modalities showed comparable effectiveness in the treatment of chronic pelvic pain related endometriosis.
Norethindrone Acetate (NETA)
Norethindrone (Norethisterone) acetate can be used continuously in a dose of 2.5 mg per day. The evidence for pain relief comes from a study by Muneyyirci-Delale and Karacan [79]. Fifty-two women with endometriosis confirmed by laparoscopy were treated with NETA. Dysmenorrhea and noncyclic pelvic pain were relieved in 48/52 (92.3 %) and 25/28 (89.2 %) of patients, respectively. Similar results were found in recurrent endometrioma [80], and adenomyosis. The advantages of NETA include, excellent cycle control, and no harmful effect on the lipoprotein profile [81]. Ferrero et al. [82] has shown that NETA can relieve the pain of endometriosis, particularly when that pain presents as dysmenorrhea.
Effect of Progestogens on Endometriosis Related Infertility
Numerous mechanisms have been proposed to explain the effect of rndometriosis in infertility:- altered folliculogenesis, reduced preovulatory steroidogenesis by granulosa cells, decreased capability etc. decreased capability of fimbrial ovum capture, sperm phagocytosis by peritoneal and oviductal macrophages, anti-sperm antibodies and reduced sperm penetration and velocity In addition, altered egg–sperm interaction, defective implantation and impaired early embryonic development have been reported to explain endometriosis related infertility. Consequently it is not surprising that although medical management improves the quality of life for many women with endometriosis, the effect on endometriosis related fertility is not so successful. Many progestational agents inhibit ovulation, precluding their use in patients desiring fertility. A Cochrane database metaanalysis [83] which included 23 trials of over 3,000 women found that pretreatment with ovulation inhibiting agents such as oral contraceptives, progestogens, danazol etc. does not improve long term fecundity, and only delays conception. Pregnancy rates following progestin therapy however, depend on the stage of the disease, and whether medical therapy is an adjunct to surgery. To date, there is no randomized controlled trial that has shown an improvement in fertility after any progestin medication. The situation may be different with progestogens which do not affect ovulation such as dydrogesterone. As stated above, dydrogesterone has been shown to improve symptoms and lead to improvement of the findings at laparoscopy. However, in women with infertility and severe disease, there is little evidence of effect on fecundity. For fertility enhancement, surgical treatment is probably preferable, with assisted reproduction immediately after surgery, prior to the recurrence of disease.
4.3 Oral Contraceptive Pill (OCP)
The estrogenic component of the OCP prevents ovulation while the progestogen is continuously supplied. A therapeutic trial is easily performed with either continuous or cyclic OCPs. Continuous administration of OCPs, avoids menstruation and its associated pain. However, absence of menstruation is not always acceptable to all women. Like progestogen regimens, the progestogen in the pill is believed to produce initial decidualization followed by atrophy. To-day the OCP is the most commonly prescribed treatment for endometriosis symptoms. A study by Guzick et al. [84] compared Lupron and continuous oral contraceptives for the treatment of endometriotic pain; both were found to be equally effective. An advantage of OCP's is that women with endometriosis are at increased risk of epithelial ovarian carcinoma. OCPs may prevent this tumor [85].
4.4 Anti-progestogens (Gestrinone)
Gestrinone is a synthetic steroid with mixed progestogen and antiprogestogen effects, some mild androgenic activity, and some anti-estrogenic activity. The mechanism of action consists of suppression of the release of pituitary gonadotropins. Gestrinone also interacts with the endometrium, inhibiting its growth. Gestrinone enhances lysosomal degradation, leading to a rapid decrease in progesterone receptors. Gestrinone is administered orally in a dose of 2.5–10 mg. weekly. A literature search in the Cochrane database [56] found no RCT comparing gestrinone to placebo or no treatment. The Gestrinone Italian Study Group [86] showed that oral gestrinone was as effective as leuprolide depot injection for pain relief. Visual analog scale pain scores decreased from 4.07 ± 2.86 to 1.23 ± 2.65 at 6 months in the gestrinone group. Two studies have compared gestrinone to danazol [87, 88]. There was no difference in either group regarding pain. Side effects are due to the androgenic and anti-estrogenic effects including, voice changes, hirsutism, and clittoral enlargement. However, most side effects are mild, transient and reversible.
4.5 GnRH Analogs
GnRH agonists are decapeptides that differ from endogenous GnRH by the substitution of one or more amino acids. GnRH agonists exert a continuous potent action on GnRH receptors leading to deep suppression of gonadotrophin secretion, ovarian suppression, hypoestrogenism, and a pseudo menopausal state. The pseudo-menopausal state leads to side effects such as hot flushes, headaches, vaginal dryness etc. and more serious effects such as bone loss. The lack of estrogen leads to remission of endometriosis during treatment. Due to frequent adverse effects, GNRH agonists are usually used as second-line treatment for endometriosis when the condition is refractory to other forms of therapy such as OCP or progestogens. Therefore, if GnRH analogs are used, concomitant add back therapy with estrogen and progestogens is indicated. The addition of estrogen and progestogen to the GnRH agonist does not seem to reduce the efficacy of GnRH agonists on pain symptoms [89]. The efficacy of GnRH agonists on endometriotic pain has been confirmed in a Cochrane database systematic review [90]. The metaanalysis included 41 trials comprising 4,935 women. The results of the metaanalysis showed that GnRH agonists are more efficient than no treatment or placebo for pain relief. However, GnRH agonists have not been shown to be superior to danazol or levonorgestrel.
GnRH antagonists do not initially release FSH and LH as the agonists, but the antagonist competes with GnRH for the receptor inhibiting any gonadotrophin release. However, the results of high quality trials are awaited/.
4.6 Danazol
Danazol is a synthetic androgen that acts by inducing atrophy of endometriotic implants. Danazol was the drug of choice for treating endometriotic pain in the 1970s and 1980s. Danazol is used in a dose of 600–800 mg per day. A Cochrane database review analysed five studies on danazol and concluded that danazol is effective for endometriotic pain compared to placebo or no treatment and improves the extent of endometriosis on laparoscopy [91]. Danazol declined in popularity due to the side effects such as weight gain, lipid profile alterations, acne, hirsutism, alopecia, mood changes, deepening of the voice, etc.
4.7 Choice of Treatment
Progestogens seem to be effective in treating endometriosis-related pain. There is however no evidence for an improved efficacy compared to other hormonal treatment and their use in the treatment of symptomatic endometriosis should be conditional to patient acceptability and tolerance of side effects. There is a problem in that the different progestogens have never been compared to one another. The LNG-IUS has been compared to Depot medroxyprogesterone acetate [70], gestrinone to leuprolide [86], and danazol [87, 88]. Danazol has been compared to medroxyprogesterone acetate [64], but there are few other comparative trials. Therefore the choice of progestogen dependant on the patients desire for conception, and often the treating physician's personal experience and preference.
The World Endometriosis Society published a Consensus on the management of endometriosis. Their recommendations are outlined in Table 9.2. However, there is no panacea for the treatment of endometriosis. The choice of treatment is dependent on the patients age, whether the main symptom is pain or difficulty conceiving, acceptability of the side effects of medical treatment, acceptability of surgery and the results of previous therapy. At present a number of new agents are being assessed for treating endometriosis (Table 9.2). These include selective estrogen receptor modulators, selective progesterone receptor modulators, statins and anti-angiogenic drugs. However, it is too soon to judge their efficacy or give recommendations.
Table 9.2
Principles of management of endometriosis (adapted from [92])
|
Treatment |
Principles for usage |
|
Surgical treatment |
1. Usually first line approach 2. Definitive diagnosis can be made 3. Depends on acceptability to patient 4. Improves fertility |
|
Medical treatment |
1. Provides symptomatic relief 2. Used for treatment of recurrences 3. Used while awaiting surgery 4. May be treatment of choice in adolescents or after menopause 5. No evidence of improvement of infertility |
|
First line medical treatment |
1. NSAIDS, OCP, progestogens 2. Choice of progestogen depends on whether ovulation should be inhibited or desire for concurrent fertility |
|
Second line medical treatment |
GnRH agonists with add back therapy, LNG-IUS |
References
1.
Cornillie FJ, Oosterlynck D, Lauweryns JM, et al. Deeply infiltrating pelvic endometriosis: histology and clinical significance. Fertil Steril. 1990;53(6):978–83.PubMed
2.
Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24:235–58.CrossRefPubMed
3.
Meuleman C, Tomassetti C, D’Hoore A, Van Cleynenbreugel B, Penninckx F, Vergote I, D’Hooghe T. Surgical treatment of deeply infiltrating endometriosis with colorectal involvement. Hum Reprod Update. 2011;17:311–26.CrossRefPubMed
4.
Leibovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 2001;75:1–10.CrossRef
5.
Sharpe-Timms KL, Piva M, Ricke EA, Surewicz K, Zhang YL, Zimmer RL. Endometriosis synthesizes and secretes a haptoglobin-like protein. Biol Reprod. 1998;58:988–94.CrossRefPubMed
6.
Piva M, Horowitz GM, Sharpe-Timms KL. Interleukin-6 differentially stimulates haptoglobin production by peritoneal and endometriotic cells in vitro: a model for endometrium-peritoneum interaction in endometriosis. J Clin Endocrinol Metab. 2001;86:2553–61.PubMed
7.
Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, Koninckx PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991;56:45–51.PubMed
8.
Taylor RN, Lebovic DI, Meuller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci. 2001;955:89–100.CrossRef
9.
Santanam N, Murphy AA, Parthasarathy S. Macrophages, oxidation, and endometriosis. Ann N Y Acad Sci. 2001;955:183–200.CrossRef
10.
Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril. 2002;77:861–70.CrossRefPubMed
11.
Eisenberg VH, Zolti M, Soriano D. Is there an association between autoimmunity and endometriosis? Autoimmun Rev. 2012;11(11):806–14.CrossRefPubMed
12.
Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76:223–40.CrossRefPubMed
13.
Gleicher N, El-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol. 1987;70:115–22.PubMed
14.
Grossinkinsky CM, Halme J. Endometriosis: the host response. Baillieres Clin Obstet Gynaecol. 1993;7:701–13.CrossRef
15.
Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17:2715–24.CrossRefPubMed
16.
Poppe K, Glinoer D, Van Steirteghem A, Tournaye H, Devroey P, Schiettecatte J, et al. Thyroid dysfunction and autoimmunity in infertile women. Thyroid. 2002;12:997–1001.CrossRefPubMed
17.
Osteen KG, Keller NR, Feltus FA, Melner MH. Paracrine regulation of matrix metalloproteinase expression in the normal endometrium. Gynecol Obstet Invest. 1999;48 suppl 1:2–13.CrossRefPubMed
18.
Garcia-Velasco JA, Arici A. Apoptosis and the pathogenesis of endometriosis. Semin Reprod Med. 2003;21:165–72.CrossRefPubMed
19.
Guo SW. Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest. 2007;63:71–97.CrossRefPubMed
20.
Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.CrossRefPubMed
21.
Gonzalez-Ramos R, Donnez J, Defrere S, et al. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod. 2007;13:503–9.CrossRefPubMed
22.
Gonzalez-Ramos R, Rocco J, Rojas C, et al. Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertil Steril. 2012;97:645–51.CrossRefPubMed
23.
Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83:149–55.CrossRefPubMed
24.
Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab. 1998;83:4474–80.PubMed
25.
Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab. 1997;82:600–6.PubMed
26.
Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248:94–103.CrossRefPubMed
27.
Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85:2897–902.PubMed
28.
Lee II, Kim JJ. Influence of AKT on progesterone action in endometrial diseases. Biol Reprod. 2014;91:63. pii: biolreprod.114.119255. [Epub ahead of print].CrossRefPubMed
29.
Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update. 2011;17(2):242–53.PubMedCentralCrossRefPubMed
30.
Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;4:406–18.CrossRef
31.
Tokushige N, Markham R, Russell P, Fraser IS. High density of small nerve fibres in the functional layer of the endometrium in women with endometriosis. Hum Reprod. 2006;21:782–7.CrossRefPubMed
32.
Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal endometriosis. Hum Reprod. 2006;21:3001–7.CrossRefPubMed
33.
Bokor A, Kyama CM, Vercruysse L, Fassbender A, Gevaert O, Vodolazkaia A, De Moor B, Fülöp V, D’Hooghe T. Density of small diameter sensory nerve fibres in endometrium: a semi–invasive diagnostic test for minimal to mild endometriosis. Hum Reprod. 2009;24:3025–32.CrossRefPubMed
34.
McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012;97:373–80.CrossRefPubMed
35.
Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. Hum Reprod Update. 2011;17:327–46.PubMedCentralCrossRefPubMed
36.
Somigliana E, Vigano P, Gaffuri B, Guarneri D, Busacca M, Vignali M. Human endometrial stromal cells as a source of soluble intercellular adhesion molecule (ICAM)-1 molecules. Hum Reprod. 1996;11:1190–4.CrossRefPubMed
37.
Jacobson TZ, Duffy JM, Barlow D, Koninckx PR, Garry R. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2009;4:CD001300.PubMed
38.
Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552–68.CrossRefPubMed
39.
Vercellini P, Somigliana E, Viganò P, De Matteis S, Barbara G, Fedele L. The effect of second-line surgery on reproductive performance of women with recurrent endometriosis: a systematic review. Acta Obstet Gynecol Scand. 2009;88:1074–82.CrossRefPubMed
40.
Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15:441–61.CrossRefPubMed
41.
Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol. 2008;111:1285–92.CrossRefPubMed
42.
Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril. 2004;82:878–84.CrossRefPubMed
43.
Vercellini P, Pietropaolo G, De Giorgi O, Daguati R, Pasin R, Crosignani PG. Reproductive performance in infertile women with rectovaginal endometriosis: is surgery worthwhile? Am J Obstet Gynecol. 2006;195:1303–10.CrossRefPubMed
44.
Koninckx PR, Timmermans B, Meuleman C, Penninckx F. Complications of CO2-laser endoscopic excision of deep endometriosis. Hum Reprod. 1996;11:2263–8.CrossRefPubMed
45.
Ford J, English J, Miles WA, Giannopolous T. Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. Br J Obstet Gynaecol. 2004;111:353–6.CrossRef
46.
Fagervold B, Jenssen M, Hummelshoj L, Moen MH. Life after a diagnosis with endometriosis—a 15 years follow-up study. Acta Obstet Gynecol Scand. 2009;88:914–9.CrossRefPubMed
47.
Kauppila A, Rönnberg L, Viehko R. Steroidrezeptoren in endometrischem Gewebe. Endometriose. 1986;4:56–9.
48.
Vierikko P, Kauppila A, Rönnberg L, Viehko R. Steroidal regulation of endometriosis tissue. Fertil Steril. 1985;43:218–23.PubMed
49.
Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear kappa B inactivation in endometriotic stromal cells. Fertil Steril. 2005;83:1530–5.CrossRefPubMed
50.
Alimohamadi S, Javadian P, Gharedaghi MH, Javadian N, Alinia H, Khazardoust S, Borna S, Hantoushzadeh S. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. J Reprod Immunol. 2013;98(1–2):52–60.CrossRefPubMed
51.
Aisemberg J, Vercelli CA, Bariani MV, Billi SC, Wolfson ML, Franchi AM. Progesterone is essential for protecting against LPS-induced pregnancy loss. LIF as a potential mediator of the anti-inflammatory effect of progesterone. PLoS One. 2013;8(2):e56161.PubMedCentralCrossRefPubMed
52.
Ragupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005;112:1096–101.CrossRef
53.
Simoncini T, Caruso A, Giretti MS, Scorticati C, Fu XD, Garibaldi S, et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis inhumanendothelial cells. Fertil Steril. 2006;86 Suppl 4:1235–42.CrossRefPubMed
54.
King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986;46(6):1062–6.PubMed
55.
Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65S:S23–7.CrossRef
56.
Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012;3:CD002122. doi:10.1002/14651858.CD002122.pub2.PubMed
57.
Overton CE, Lindsay PC, Johal B, Collins SA, Siddle NC, Shaw RW, Barlow DH. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril. 1994;62(4):701–7.PubMed
58.
Strowitzki T, Faustmann T, Gerlinger C, et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151:193–8.CrossRefPubMed
59.
Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2011;52:1704–13.CrossRefPubMed
60.
Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633–41.CrossRefPubMed
61.
Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51:188–215.CrossRefPubMed
62.
Zimmermann H, Duvauchelle T, Gualano V, Kaufmann G, Bervoas-Martin S, Breitbarth H. Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol. Drugs Today. 1999;35(Suppl C):27–39.
63.
Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand. 2001;80:628–37.CrossRefPubMed
64.
Telimaa S, Puolakka J, Ronnberg L, et al. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987;1:13–23.CrossRefPubMed
65.
Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril. 2000;74:24–30.CrossRefPubMed
66.
Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175:396–401. Brown.CrossRefPubMed
67.
Sclaff W, Carson S, Luciano A, Ross D, Bergvist A. Subcutaneous injection of depot medoxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis associated pain. Fertil Steril. 2006;85(2):314–25.CrossRef
68.
Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77(1):52–61.CrossRefPubMed
69.
Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90.CrossRefPubMed
70.
Streuli I, de Ziegler D, Santulli P, Marcellin L, Borghese B, Batteux F, Chapron C. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013;14(3):291–305.CrossRefPubMed
71.
Engemise SL, Willets JM, Taylor AH, Emembolu JO, Konje JC. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol. 2011;157:101–6.CrossRefPubMed
72.
Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod. 2004;19:179–84.CrossRefPubMed
73.
Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305–9.CrossRefPubMed
74.
Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–8.CrossRefPubMed
75.
Serachioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94:464–71.CrossRef
76.
Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–26.CrossRefPubMed
77.
Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50:273–9.CrossRefPubMed
78.
Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–6.CrossRefPubMed
79.
Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998;43:24–7.PubMed
80.
Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafia O. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health. 2012;4:149–54.PubMedCentralCrossRefPubMed
81.
Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol. 2002;187:1101–16.CrossRefPubMed
82.
Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, Remorgida V. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150:199–202.CrossRefPubMed
83.
Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2007;3:CD000155. Review.
84.
Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011;95(5):1568–73.PubMedCentralCrossRefPubMed
85.
Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–40.CrossRefPubMed
86.
Gestrinone Italian Study Group. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Fertil Steril. 1996;66:911–9.
87.
Bromham DR, Booker MW, Rose GL, Wardle PG, Newton JR. A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. J Obstet Gynaecol. 1995;15:188–94.CrossRef
88.
Fedele L, Arcaini L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril. 1989;51(5):781–5.PubMed
89.
Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22:283–8.PubMed
90.
Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010;CD008475.
91.
Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2007;CD000068.
92.
Johnson NP, Hummelshoj L; Consensus on current management of endometriosis. World Endometriosis Society Montpellier Consortium. Hum Reprod. 2013;28:1552–68.PubMed